Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte’s Oncology Pipeline March 15, 2023
Volastra Therapeutics in-licenses Clinical Stage KIF18A Inhibitor And Secures $60 Million in Series A Funding To Further Advance Cancer-Focused Pipeline March 15, 2023
Tachyon Receives Funding from CIRM for a Ph 1 Study of TACH101 in Patients with Advanced Solid Tumors March 15, 2023
Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments March 15, 2023
Enrollment initiated in Ph 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer March 15, 2023
Ph 3 KEYNOTE-671 Trial Met Primary Endpoint of EFS in Patients With Resectable Stage II, IIIA or IIIB NSCLC March 15, 2023
Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Mets from NSCLC March 15, 2023
Tagrisso demonstrated strong OS benefit in the ADAURA Ph 3 trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer March 15, 2023
Imfinzi significantly improved EFS in AEGEAN Ph 3 trial for patients with resectable NSCLC March 15, 2023
KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma March 15, 2023
ACE-Breast-02 Pivotal Ph 3 Study of ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results March 15, 2023
FAILED TRIAL: Ph 3 CONTACT-03 study of cabozantinib + atezolizumab versus cabozantinib alone in RCC patients did not meet primary endpoint of PFS March 15, 2023
Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumour Types in DESTINY-PanTumor02 Ph 2 Trial March 15, 2023
FDA Advisory Committee Votes In Favour of the Clinical Benefit of Polivy Combination For People With 1L DLBCL March 15, 2023
FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer March 15, 2023
FDA Clearance of IND Application for Phase 1/2 Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas March 15, 2023
Libtayo® (Cemiplimab) + Chemotherapy combo Receives Positive CHMP Opinion For The Treatment Of Advanced PD-L1 Positive NSCLC March 15, 2023
FDA accepts Supplemental BLA and EMA Validates Application for Opdivo as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma March 15, 2023
Update provided on US Regulatory Review of LYNPARZA + Abiraterone in metastatic CRPC patients March 15, 2023
